A comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists shows significant benefits in kidney and cardiovascular outcomes for individuals with and without diabetes. GLP-1 receptor agonists are known for treating diabetes and obesity by mimicking glucagon-like peptide 1 hormone actions. A meta-analysis of 11 clinical trials involving over 85,000 participants confirmed a 19% reduction in the risk of kidney failure and improved kidney function with GLP-1 receptor agonists. These drugs also showed a 14% reduction in the risk of cardiovascular events and a 13% reduction in overall mortality. The study highlights the importance of GLP-1 receptor agonists in treating chronic kidney disease and cardiovascular conditions globally.
Source link
Popular diabetes and obesity drugs also protect kidneys, study shows
